Byrne Lee, MD, FACS
Dr. Byrne Lee is a surgical oncologist and specialist in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. The treatment has proven to be effective in the treatment of malignant peritoneal mesothelioma, an asbestos-related cancer. He sees patients at the Stanford Cancer Center in Palo Alto, California, where he is a Clinical Professor of Surgery and Director of Regional Cancer Therapies.[1]
Dr. Lee’s special interests include the treatment of all types of gastrointestinal malignancies. His career is dedicated to the surgical management of metastatic diseases of the liver and peritoneum. He uses minimally invasive and robotic surgical techniques, as well as traditional open surgery, to treat cancers of the stomach, liver, pancreas, small intestine, colon, and soft tissue sarcoma.
Education and Career
Dr. Lee attended the Sophie Davis School of Biomedical Education at the City College of New York and received his medical degree from New York Medical College. He completed an internship and residency in General Surgery at Lenox Hill Hospital and fellowship training in Surgical Oncology at the City of Hope National Cancer Center.[1]
After completing his medical education and training, Dr. Lee remained at the City of Hope, where he led the Peritoneal Surface Malignancy Program before joining Stanford Cancer Center. Over the years, he has trained and mentored hundreds of surgical residents and medical students, for which he has received multiple awards for his teaching talent and clinical mentorship.
Professional Memberships and Activities
Dr. Lee is a member of a national consensus group performing collaborative research and developing clinical trials for HIPEC surgeries. He is a fellow of the American College of Surgeons and a member of the American Society of Clinical Oncology.[1]
Research
Dr. Lee leads Stanford’s Regional Cancer Therapies program, which works to develop novel treatment strategies for patients diagnosed with peritoneal malignancies and oligometastatic diseases of the liver. His research focus is on clinical outcomes of multidisciplinary management for gastric, hepatobiliary, and peritoneal surface malignancies.[1]
His publications and presentations include:[2]
Preoperative CA 19-9 Predicts Disease Progression in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy:… Fackche, N., Schmocker, R., Nudotor, R., Kubi, B., Cloyd, J., Grotz, T., Fournier, K., Dineen, S., Veerapong, J., Baumgartner, J., Clarke, C., Patel, S., Wilson, G., L…> ; Annals of Surgical Oncology. 2024 Feb 3
Understanding the Caregiver Perspective: The Impact of Caring for Patients with Advanced Cancer. Sun, B., Lee, B.>; Annals of Surgical Oncology. 2024 Jan 29
GITR and TIGIT immunotherapy provokes divergent multicellular responses in the tumor microenvironment of gastrointestinal cancers. Anuja Sathe, Carlos Ayala, Xiangqi Bai, Susan M Grimes, Byrne Lee, Cindy Kin, Andrew Shelton, George Poultsides, Hanlee P Ji>; Genome Medicine. 2023 Nov 26
Journal Articles
Lymphovascular Invasion Predicts Lymph Node Involvement in Small (<2 Cm) Appendiceal Neuroendocrine Tumors. Andrew M Blakely, Mustafa Raoof, Byrne Lee, Journal of The American College of Surgeons
A Collaborative Surgical Approach to Upper and Lower Abdominal Cytoreductive Surgery in Ovarian Cancer. Byrne Lee, Mark T Wakabayashi, Ernest S Han, Thanh H Dellinger, Andrew M Blakely, Bertram Yuh, Journal of Surgical Oncology
Authored Content
Lymphovascular Invasion Predicts Lymph Node Involvement in Small (<2 Cm) Appendiceal Neuroendocrine Tumors October 2018
